Creso Pharma Set for Big 2020 with Pharmaceutical Cannabis Expansion

The legal cannabis market is forecast to reach US$148 billion by 2026, with Barclays European Consumer Staples Report predicting the global cannabis market will reach US$272 billion by 2028.

Surprisingly, despite still stringent legislation, the Australian legal cannabis market is also experiencing heightened activity.

Australia’s Office of Drug Control has so far issued 69 licenses to cultivate, produce, or manufacture medicinal cannabis.

This includes:

  • 24 licenses for cultivation of cannabis for medicinal use,
  • 16 for cultivation for research, and
  • 23 for manufacture of medicinal cannabis products.

Creso Pharma Ltd (ASX: CPH) has established itself in this market as an early mover within the medicinal cannabis sector. Its focus: high margin pharmaceutical-grade cannabis products in human and animal health.

As a global entity, Creso represents an early entry point for investors to dip their toes in the global legal cannabis market.

The company has a diverse product portfolio of cannabis and hemp-derived products focused on four key areas: therapeutics, nutraceuticals, animal health, and cosmetics.

Since 2016, it has been committed to build a business rather than ride a trend, albeit a potential lucrative one.

Within this environment, Creso is aggressively pursuing the launch of nine pharmaceutical-grade products, along with key certifications and strategic partnerships that will accelerate revenue growth.

Creso has already launched four sales generation products across the cosmetics, animal health, nutraceuticals, and therapeutics verticals.

The company expects its growth plans to be supported by funding measures, revenue increases, and cost management initiatives.

While its operations continue to move from strength to strength, it hasn’t been smooth sailing for the company in 2019.

A failed takeover bid by Canadian cannabis giant PharmaCielo Limited (TSX-V:PCLO) which targeted Creso for the breadth and strength of its current portfolio rocked its share price.

Te bid valued Creso at A$122 million; the deal fell over in November due to a softening in the broader medicinal cannabis market.

It did, however, highlight the potential invesment opportunity in the ASX listed Australian company.

The proposed takeover valued Creso at 63 cents per share. The most recent placement was conducted at 19 cents per share – the takeover price representing a 230% premium.

Creso’s strengths are emphasized by its year-on-year revenue growth, providing a sound base as new products are brought to market.

The company recently launched its cannaQIX® range in Africa in conjunction with leading South African pharmaceutical company, Pharma Dynamics, a subsidiary of Lupin Limited (NSE: LUPIN). Initial orders worth approximately A$300,000 for the cannaQIX® product range have been made and Creso anticipates the products will available in South Africa in Q1 2020.

In animal health, Creso’s partner Verbal is introducing the two initial anibidiol® products into further countries in Europe and will be launching Creso Pharma’s new animal health products in the near future.

For both human and animal health, Creso has initiated its reach into North America, where it is in discussions with a number of potential partners to introduce all 13 products, human and animal, into selected US states.

Products are made with standardized dosing and formulations through the application of pharmaceutical rigor, Good Manufacturing Practices (GMP) standards, and proprietary, innovative delivery technologies.

In addition, they carry the well-known “Swiss Made” label that is synonymous with premium-quality products.

The Swiss connection is significant as Swiss-based CEO Dr. Miri Halperin Wernli is a well-regarded senior Pharma executive with over 24 years of strategic and operational leadership in global drug and product development in the pharmaceutical and biomedical industries.

Creso believes the value of its fundamental operations continues to grow, supported by the company’s portfolio of products, established operations, corporate interest, and global market opportunities.

To learn more about Creso Pharma visit The Next Biotech.

End


Evidence of Inflated Test Results Emerges in Nevada

A Washington state scientist and cannabis consumer advocate has discovered evidence of “lab shopping” in Nevada using state cannabis laboratory data. Jim MacRae used publicly available lab results from Nevada’s busiest nine testing labs from January 2018 to May 2019. He was particularly interested in the failure rates for biological pathogens, heavy metals and pesticides, and potency results. After some negotiation, the state provided over eighty thousand “blind” data points for MacRae to analyze this summer.

Expecting a 10 – 15 % sample failure rate, MacRae instead found that some labs routinely had less than ten percent failure rates and one lab had no fails for a 14-month period, which raised red flags. Many of these same labs reported higher than usual THC rates, according to his report.

MacRae met with regulators in September, who quickly moved to address the problem.

“What impressed me most is how rapidly Nevada escalated the issues suggested by the data and also by how quickly the state acted. I presented my work on a Thursday afternoon and met with members of a number of different government departments on Friday. The following Monday, the Department of Taxation published a notice to the labs that put them on notice that the Department was ‘aware of and investigating potential inflation of THC levels by cannabis laboratories” and that such behavior was not acceptable.’ — Jim MacRae, in a blog post explaining the results.

Despite providing “blind” data, the state is aware of the problem labs’ identities, MacRae said.

“They could do much more by revealing what labs have the problems and what products are affected,” MacRae said in a phone interview with Ganjapreneur. “But, Nevada has done more in three days than Washington regulators have done in three years about similar problems in the Washington market, so I applaud what Nevada has done so far.”

According to the Nevada Current, the state has only suspended Certified AG Lab’s license, but has not made public the other labs and products in question. Instead, Nevada is asking consumers to “take caution” when buying cannabis products tested by Certified AG Lab. 

MacRae has asked for a second round of data from Nevada with the identity of the labs revealed; he said he will know soon if they grant his request.

End


MLB Considers Not Testing Minor Leaguers for Cannabis

Major League Baseball is considering removing cannabis from the banned substance list for minor league players while implementing an opioid testing program in both the minor and major leagues, according to a CBS Sports report. The proposal was first reported by The Athletic’s Ken Rosenthal.

According to the report, players on the 40-man roster are not tested for cannabis but non-40-man roster minor league players are, and 13 players were suspended last season for cannabis use. Rosenthal says major league players “have not been subject to testing for marijuana.”

The opioid testing proposal comes more than five months after the death of Los Angeles Angels pitcher Tyler Skaggs who had two different types of opioids in his system at the time of his death. Players who fail an opioid test would be referred to treatment rather than suspended.

Under the current rules, non-40-man roster minor leaguers are suspended 25 games for their first positive test for a “drug of abuse” – which includes cannabis – 50 games for a second positive test, 100 games for a third positive test. A fourth positive test bans a player for life. To date, no minor leaguer has been banned for life for cannabis use, although former Brewers relief pitcher Jeremy Jeffress was suspended three times for cannabis use. Jeffress was released by the Brewers on September 3 after an injury-shortened campaign.

Alongside cannabis, the MLB’s list of “drugs of abuse” are synthetic cannabinoids, cocaine, LSD, opiates, MDA, MDMA and ecstasy, “bath salts,” GHB, and PCP.

The league and players association have yet to finalize the new drug testing agreement.

End


Brooklyn DA Drops Charges Against Hemp Shipment Recipient

The Brooklyn District Attorney’s Office has told a judge it is dropping all charges against the man who received a 106-pound shipment of legal hemp but was arrested after FedEx called in a tip about the shipment, the New York Post reports.

On Tuesday, Prosecutor Kerri Row told Judge Raymond Rodriguez that the DA’s office had been “presented with evidence that the substance seized in [the] case contains less than .06 percent THC, which makes the substance legal hemp under federal and now state law.”

“The new law places the development and enforcement of regulations pertaining to hemp squarely in the jurisdiction of the [state] Department of Agriculture, and in light of this, we consider this case to be more appropriately dealt with as a regulatory than a criminal matter. Accordingly, pursuant to our prosecutorial discretion, we move to dismiss the charges in this case.” – Brooklyn Assistant District Attorney Row, during court proceedings, via the Post

Despite the move to drop charges, Row said the NYPD would remain in possession of the shipment because it “appears to have been imported outside of New York’s regulatory guidelines.” She added that “the release of the property would be a determination to be made by the NYPD in consultation with the Department of Agriculture.”

In a statement to the Post, the NYPD maintained that the hemp plants were “illegal marijuana” because in New York “hemp sale and possession/distribution is only permissible when the buyer and seller have the proper permissions from the New York State Department of Agriculture and Markets” and the business owner did not get those permissions.

The case stems from the November 5 arrest of Ronen Levy, whose brother, Oren, owns Green Angels CBD and had ordered the hemp from a Vermont farm. Ronen had picked up the FedEx shipment because his brother was recovering from surgery. Oren said the packages seized by police contained laboratory testing paperwork that showed the plants contained THC levels below legal limits. About 10 days after the arrest, the DA’s office indicated they would drop the charges, but Ronen was given a new hearing date during his last court appearance earlier this month before the charges were ultimately dropped on Tuesday.

Sanford Rubenstein, an attorney for Green Angel, told the Post that the company would be filing a $10 million lawsuit against the NYPD and New York City.

End


Study Shows Cannabis Use Does Not Affect Next-Day Driving

A study by the Toronto, Canada-based Centre for Addiction and Mental Health found that while drivers under the influence of cannabis shows signs of driving impairment immediately after consumption, they performed normally in driving tests 24 and 48 hours later, according to a Global News report outlining the study.

The study, using a driving simulator, allowed participants to control their own cannabis consumption, which varied the THC in the blood of the subjects and ranged from zero to 42 nanograms per milliliter – which is about 10 times more than the legal limit in Canada.

Immediately after smoking, the group that consumed THC drove inappropriately slowly and centered the simulated car in the lane poorly.

“We found significant evidence of difference in driver behavior, heart rate and self-reported drug effects 30 minutes after smoking cannabis, but … we found little evidence to support residual effects,” the researchers said.

Scott Macdonald, a retired professor at the University of Victoria, said the nation’s drugged driving laws – which require no trace of THC when operating a vehicle – are “not scientific” and argued that the 24-hour after-effects of cannabis are a myth.

“When people smoke cannabis, they’re only impaired for a short, short period of time. You could have THC in your bloodstream, but you’re not a danger,” he told Global News.

“The biological tests are not useful for identifying people that represent a safety risk. What we’re left with is behavioral symptoms. We’re still working on developing tests to assess whether an individual who consumes cannabis is a safety risk. It’s hard to do. Cannabis is not in the same class as alcohol, in terms of safety risk. Alcohol is much, much worse.” – Macdonald, to Global News

Drugged driving laws throughout Canada vary – in Ontario, drivers found with any THC in their system face a three-day license suspension, $250 fine, and $281 reinstatement fee for their first offense. In Saskatchewan, new drivers face a 60-day license suspension, three-day vehicle seizure, and four points.

In Saskatoon, Saskatchewan’s largest city, police reported that just eight of 292 driving while impaired violations from Oct. 17, 2018 to Oct. 17, 2019 were directly related to cannabis intoxication. Since July 2019, the agency has employed a Draeger 5000 Roadside Screening Device “at every sobriety checkpoint” to test for both cannabis and cocaine and have used it 12 times; nine drivers tested positive for THC, while two drivers were cleared of driving under the influence due to the device’s results.

End


Report: Legal Canadian Cannabis Has 95% Pesticide Test Pass Rate

Just five percent of legally-grown Canadian cannabis contained pesticides, according to Health Canada data outlined by Global News. Five of 133 samples tested by the agency had restricted pesticides, while four tested positive for pesticides within acceptable ranges.

One sample tested on Dec. 12, 2018 – two months after legalization – contained levels of myclobutanil, a mildew killer and known carcinogen, at 14 ppm. When burned, myclobutanil produces hydrogen cyanide. The sample also contained bifenazate at 3.1 ppm; both chemicals are limited to 0.020 in dried flower.

Tammy Jarbeau, a spokesperson for Health Canada, told Global News that a recall was issued for the product and “at the time of the product recall, the pesticide testing had not yet been completed.”

“Licensed cultivators and processors are required to report the detection of unauthorized pesticide active ingredients (a positive test result) to Health Canada no later than seven calendar days following receipt of the test results.” — Jarbeau, to Global News

In 2017, the agency performed 160 unannounced tests of the then-medical only cannabis industry and had about 40 products come back with positive pesticide results; 28 of which for myclobutanil.

Since legalization, Health Canada has issued 17 product recalls. Montreal monopoly retailer, Société québécoise du cannabis, told Global News that they haven’t recalled any products as the result of testing, while the Alberta Gaming and Lottery Corporation appears to have paid for six cannabis tests, of which two failed. The Ontario Cannabis Retail Corporation said they don’t conduct testing.

End


Canopy Growth Names Constellation Brands CFO as CEO

Canadian cannabis producer Canopy Growth has named Constellation Brands Executive Vice President and Chief Financial Officer David Klein as its new chief executive officer. Klein has served in senior leadership roles at the alcohol distribution firm for 14 years and will take over for Mark Zekulin who took over as sole CEO following the ouster of company founder Bruce Linton.

Constellation, which distributes Svedka vodka and Corona beer, owns about 38 percent of Canopy after making its first investment in the company – then just 9.9 percent – in 2017. Last year, Constellation made a then-record $4 billion investment into the cannabis firm, more than tripling its share.

Klein, who will step down from all other positions when he takes over the reins on January 14, said “no company is better positioned to win in the emerging cannabis market” than Canopy.

“I look forward to working with the team to build on the foundation that has been laid, to develop brands that strongly resonate with consumers, and to capture the market opportunity before us. Together we will drive sustainable, industry-leading growth that benefits employees, shareholders and the communities in which we operate.” – Klein, in a press release

Klein is currently the chairman of Canopy’s board of directors which also counts Constellation executives Bill Newlands, Judy Schmeling, and Robert L. Hanson among its members. Linton indicated at the time of his dismissal that he had fallen out of favor with those directors but said he had “full confidence” in its leadership team.

Zekulin, who founded Canopy with Linton, will resign from his seat on the board on December 20.

End


Saskatoon, Saskatchewan Police Cite ‘Fewer Issues Than Expected’ After Legalizing

Police in Saskatoon – the largest city in Saskatchewan, Canada – said they’ve arrested less than 200 people for cannabis offenses in the year since legalization and that they “experienced fewer issues than were expected.”

In a report issued November 28, police said 11 of those charges were federal, including: sales and distribution (6), possession over the legal limit (2), distribution to minors (1), an illegal sale to an adult, and an illegal dispensary. The non-federal charges include: possession or consumption in a vehicle (55), possession by a minor (50), consumption in public (31), possession of “cannabis known to be illicit” (18), possession over 30 grams in public (16), sales- and distribution-related charges (12), and distribution to a minor (1). Police filed no charges for cannabis consumption on school grounds.

The report notes that just eight of 292 driving while impaired violations from Oct. 17, 2018 to Oct. 17, 2019 were directly related to cannabis intoxication. Since July 2019, the agency has employed a Draeger 5000 Roadside Screening Device “at every sobriety checkpoint” to test for both cannabis and cocaine and have used it 12 times; nine drivers tested positive for THC, while two drivers were cleared of driving under the influence due to the device’s results.

Saskatoon Police said that the largest illicit cannabis bust in the city was part of “an operation with a larger scope” in which a “known street gang member” had about 3.5 kilograms of cannabis and 960 grams of concentrates.

End


Personalized Cannabis Care Now Available Through Veriheal

New York, New York, December 10, 2019 — For those who are keen on getting their medical cannabis cards, the process can be somewhat intimidating, especially if they are unaware of the nuances. While each state program might slightly differ, the steps to getting a medical cannabis card are fairly straightforward across the board. In states with an active medical cannabis program, it is required that prospective patients become ‘certified’ before sending their application and information to the designated governing body. While this infrastructure appears to be sound and stable, it does pose some potential problems down the road for the patient. 

Since cannabis is largely understudied and not completely backed by authoritative research, the standard healthcare professional is not likely to be well-informed about it as a whole. While doctors can ‘recommend’ or ‘approve’ of cannabinoid therapy, their expertise usually ends there and renders them unable to offer any further guidance. This leaves patients to fend for themselves in an uncharted and confusing market where the law is not clearly laid out in black or white. It can be scary for some and even be off-putting which will ultimately turn people away from potential options that could have been legitimately beneficial. 

Since companies in the cannabis sector are not allowed to make any medical claims, they resort to submitting disclaimers to avoid any legal ramifications. Product and website disclaimers will tell people to seek the advice of a medical professional before using cannabis products. But when most physicians have little to no advice to give, therein lies a big problem. This is where Veriheal steps in as a guiding beacon of light. 

Bonafide experts are the ones that are looked up to for advice. Nutritionists, dieticians, fitness experts and the like all have specialized knowledge that lets them be able to formulate wellness plans that fit their client’s interests. The cannabis industry is in a critical need for such experts who are willing to educate the general public and provide patients with some clarity on what products to use or, how to use them, and where to access them. 

Veriheal is renowned for its swift and effortless medical cannabis card consults. But recently, the company introduced a new personalized cannabis consultation service that addresses the discrepancy between uninformed physicians and their patients. The greatest thing about this new service is that it is available for everyone across all 50 states. The experts conducting these consultations are a team of qualified medical professionals who are well versed in scholarly cannabis research and can thoroughly educate anyone that is interested in turning to medical cannabis therapy. This information is available for everyone, even those who reside in prohibition states. 

These discreet personalized cannabis consults are geared toward anybody who is interested in pursuing alternative cannabis medicine, one does not need to already be an active patient in their state program. These assessments are simply a one-on-one discussion with a specialist who can further target and refine their recommendations based on a patient’s individual interests. After their appointment, patients will receive an in-depth suggested strategy covering information such as cannabinoid and terpene profiles to target, individual state laws, and guidance on due-diligence. Everything is individually tailored to accommodate the patient’s needs and desires. Should those needs change, patients can certainly book another follow-up to speak with the experts further. Veriheal’s main goal is for everyone to leave their appointment with confidence and reassurance. They will be able to go on and properly navigate the cannabis market on their own accord or move forward and apply for their medical cannabis card should they decide to do so. 

In order to successfully implement cannabis reform, it is necessary to educate where possible. Veriheal is at the forefront of the movement, and eager to improve the public’s perception of cannabis and offer encouragement for those who might be hesitant to come forward to discover cannabis. By offering easy avenues for patients to get their medical cards and informational treatment consults that are specially built for the individual, they make a point to put the patient’s needs first. They believe patients have the right to take charge of their healing. By giving the power to the patients, the stigma will one day be broken. 

About Veriheal
Veriheal is a healthcare technology company with a mission to provide personalized cannabis education and wellness to everyone around the world. The company does that by connecting patients and doctors online, through their platform, to provide recommendations for living a better life. 

Contact
Veriheal
https://www.veriheal.com/contact-us/

End


XFL Won’t Include Cannabis in Drug Testing Protocols

The XFL, an alternative, off-season football league led by World Wrestling Entertainment Chairman Vince McMahon, will reportedly not include cannabis among their drug testing protocols, according to an American Football International report. WWE talent – who are considered contractors – are tested for cannabis, however, and fined $2,500 per positive test.

In May, XFL Commissioner Oliver Luck told Sports Illustrated that the league would “prefer not to test for marijuana” but would test for performance-enhancing drugs. The lack of testing for cannabis could make the fledgling league an alternative for players who have left the NFL for cannabis use. Last year, the league denied free agent running back Mike James a therapeutic use exemption for cannabis to manage pain; however, James was not included in the XFL draft. In April, retired NFL player Martellus Bennett estimated that 89 percent of players in the league use cannabis.

Earlier this year, the NFL and NFL Players Association announced the creation of a Joint Pain Management Committee that would include cannabis as part of its research into pain management and alternative therapies.

The XFL, to its credit, experimented with several changes to football during its first — and only — season in 2001, including the sky camera and relaxed celebration policies which were both eventually adopted by the NFL. The XFL cannabis policies could impact the NFL this time around if it were to result in players choosing to take their talents to off-season league. In all, 71 players were drafted in the XFL draft in October to eight teams; there are expected to be about 500 players throughout the league.

The league kicks off February 8.

End


Entire Civilized Magazine Staff Laid Off After Takeover

Cannabis data analytics company New Frontier is moving forward with its acquisition of cannabis media company Civilized and have laid off all 16 employees and halted all operations as it addresses “areas of improvement,” according to a report from Huddle. The layoffs affected all nine employees at Civilized’s Saint John, New Brunswick, Canada headquarters and all seven at its Los Angeles, California office.

New Frontier founder and CEO to Giadha Aguirre de Carcer said that Civilized would resume operations next month but could not offer specifics about what the company would look like going forward. Aguirre de Carcer said that it’s “too soon to say” if Civilized would have operations in Saint John or Los Angeles.

In a statement to Huddle, New Frontier said they while Civilized has had “tremendous success” with events – such as the World Cannabis Congress – the company wasn’t sure whether they would continue with the events.

“As lucrative cannabis markets continue to emerge in North America and around the world we only expect demand to grow for high-quality industry events such as the World Cannabis Congress and look forward to putting the right plan in place to ensure the long-term success of this and other Civilized events.” – New Frontier, in a statement to Huddle

The news from New Frontier is the latest shakeup in the cannabis media space. In late October, the majority of DOPE Magazine’s Seattle editorial team was laid off by High Times – which acquired DOPE last year – and the office was shuttered. High Times CEO Kraig Fox called the move a “strategic decision” but noted that some employees had accepted positions at the company’s Los Angeles headquarters. Less than two months after the layoffs, Hightimes Holding Corp., said in a Securities and Exchange Commission filing that there was “substantial doubt” about whether the company would continue operations.

Last week, cannabis social media network MassRoots went dark after years of raising capital, losing money, and problems at the very top of the company.

Hightimes Holding also bought Green Rush Daily and CULTURE magazine last year for $7 million and $4 million, respectively.

End


University of Alberta to Study Cannabis Treatment for MS, Alzheimer’s, and Huntington’s

Canadian medical cannabis producer Atlas Biotechnologies has given a $300,000 grant to the University of Alberta for research into cannabis as a therapy for multiple sclerosis (MS), Alzheimer’s disease, and Huntington’s disease, the Edmonton Journal reports. Throughout the U.S. and Canada, those conditions are already often approved for medical cannabis access but the researchers hope to find scientific proof as to why it works.

“There isn’t solid scientific evidence for most of what people are saying about cannabis,” said Ross Tsuyuki, U of A pharmacology department chair who is supervising the research. “We have the researchers that know these conditions that are possible targets for where cannabis could be beneficial.”

The funding agreement allows researchers full autonomy over how the study is conducted and how the results are used.

“The thing that we’re conscious of is that we can’t have industry driving the research. We have to have our independence. We need to have the freedom to design experiments in ways that are scientifically valid and to get the best answer possible.” – Tsuyuki, to the Journal

Anne Taylor, a pharmacology professor at the university, said she hopes the research will limit the use of opioids in pain management for the conditions.

“We are living in an opioid epidemic,” she said in the report. “There’s a strong need to develop novel, non-addicting therapies to try and manage chronic pain. We’re interested in utilizing the utility of cannabis, or cannabinoids, as being one of those types of drugs.”

The research associated with the funding is expected to take two years.

End


WSU Study: Cannabis Companies More Concentrated in Poor Neighborhoods

A study by the Elson S. Floyd College of Medicine at Washington State University has uncovered economic disparities in the distribution of cannabis producers, processors, and retailers throughout the state. Relying on Washington State Liquor and Cannabis Board (WSLCB) data and Census Bureau data collected between 2014 and 2017, the study found that lower socioeconomic neighborhoods had a 159% higher density of producers, a 120% higher processor density and a 259% higher cannabis retail store density when compared to more “affluent neighborhoods.”

“Our mission at the Elson S. Floyd College of Medicine is to understand challenges facing rural and underserved communities, and this study shows that disadvantaged communities in Washington have disproportionate numbers of cannabis businesses,” said Solmaz Amiri, a postdoctoral research associate in the department of nutrition and exercise physiology and one of the authors of the study. “Having this insight is an important step toward better understanding how cannabis businesses can impact the health of individuals and communities.”   

Although the exact causes for the uneven distribution are beyond the study’s scope, researchers point to generally lower resistance to these types of businesses in poorer neighborhoods and lower real estate costs. Others point to Washington’s proximity laws, which insist cannabis businesses must be one thousand feet from schools, playgrounds, and youth centers. 

“States, local authorities, and policy makers have started developing regulations for the cannabis industry without knowing the public and health impacts of such regulations. We need to understand the specific needs and challenges of communities impacted by the legalization of cannabis, such as if legalization is increasing consumption and the impact of legalization on neighborhoods and crime.” — Amri, via WSU Insider

End


The Emerald Cup Returns Dec. 14-15 to the Sonoma County Fairgrounds

Bringing Top Cannabis Experts, Educators and Farmers Together with Consumers, Featuring: 500+ Contest Entries // 300+ Brands // 160+ Speakers // 100+ Educational Sessions & Podcasts // 20+ Music Acts & Much More!

FLATBUSH ZOMBIES CONFIRMED TO HEADLINE MUSIC LINEUP 

Also Featuring Performances from Santigold, Steel Pulse, Emancipator, the Redwood Stage Presented by Northern Nights Stage with DJ Craze, Cofresi & Much More

ANNOUNCE REDWOOD EMPIRE FOOD BANK FOOD DRIVE, DAY OF SERVICE TREE PLANTING AND HEADCOUNT CANNABIS VOTER PROJECT

UNVEIL EMERALD TALKS SCHEDULE FEATURING SPEAKERS INCLUDING:

NBA Star and Cannabis Advocate Matt Barnes, Peter Tosh Estate Executor Niambe McIntosh, Cannabis Entrepreneur & The Notorious B.I.G.’s Son Christopher Wallace, Dr. Bronner CEO David Bronner, Wine Enthusiast Magazine’s Virginie Boone, California Department of Fish and Wildlife’s Ryan Mathis, NORML’s Justin Strekal & Much More

DOWNLOAD THE JUST-LAUNCHED APP FOR SCHEDULE & UPDATES HERE 

The Emerald Cup returns December 14 & 15, 2019 for the 16th annual competition and festival, bringing top cannabis experts, educators and farmers together with consumers. The event is the largest, most-respected organic outdoor cannabis competition in the world and will be held at the Sonoma County Fairgrounds in Santa Rosa, CA. Named for the Emerald Triangle growing region of Northern California’s Mendocino, Humboldt and Trinity counties, the Cup celebrates Emerald Triangle’s harvest and will feature over 500 contest entries this year. The weekend will also feature performances from just-announced Saturday headliner Flatbush Zombies as well as Santigold, Steel Pulse, Emancipator, The Polish Ambassador, Expendables, the Redwood Stage presented by Northern Nights Music Festival with DJ Crazy, Cofresi and much more (previously announced performer DJ Snoopadelic will no longer be performing due to a scheduling conflict). 

For the first time, Emerald Cup will also have an app available for both iOS and Android users. With such vast and diverse reprogramming, attendees are encouraged to download the app for real time updates throughout the weekend and to better enhance their festival experience. The app, full weekend schedule and tickets for 21+ patrons are available now at https://theemeraldcup.com

To encourage community service in the Emerald Cup family, the event producers have announced multiple service-related endeavors in partnership with Santa Rosa. Prior to the event, the Emerald Cup team will be helping nurture the health of the Martin Luther King Jr. Park by planting and re-staking trees for the public to enjoy for years to come. The Emerald Cup will also host a food drive benefiting the Redwood Empire Food Bank (https://refb.org). While patrons can bring individual items for donation, Redwood Empire Food Bank would prefer bags of “full meal” donations that would include ingredients for a full meal such as pasta, pasta sauce, along with fruits and veggies. “In acknowledgement of the recent and ongoing trials our community is facing, from the fires and power outages to the continuing changes and challenges with industry regulations, we have decided to direct our energies toward service to our community,” notes Emerald Cup founder and producer Tim Blake.

The Emerald Cup has also developed into the destination for agricultural experts, industry innovators, health and wellness advocates, cultural enthusiasts and the canna-curious to celebrate and expand their horizons. The Marketplace allows attendees to taste the terroir of California, featuring vendors including 20 seed companies bringing exclusive releases to the event and sungrown cannabis vendors from throughout the state. The weekend will see 300 brands including sponsors Cookies, The Botanist, Flow Kana, Elyon, Connected Cannabis, Alien Labs, Hempire and SC Labs; over 100 educational sessions & podcast recordings (more info HERE) featuring over 160 speakers including NBA Star and cannabis advocate  Matt Barnes, Peter Tosh’s Estate executor and daughter Niambe McIntosh, cannabis entrepreneur and The Notorious B.I.G.’s son C.J. Wallace, Dr. Bronner CEO David Bronner, Wine Enthusiast Magazine’s Virginie Boone, California Department of Fish and Wildlife’s Ryan Mathis, and NORML’s Justin Strekal; and much more. HeadCount’s Cannabis Voter Project will also be with us this year, making some noise and registering voters at their booth where people can pick up a FREE Cannabis Voter pin.

For the full Emerald Cup schedule and more, visit: https://theemeraldcup.com

FOLLOW THE EMERALD CUP  

https://theemeraldcup.com

Instagram * Facebook * Twitter

End


75% CBD Directly Compressible Granulates to Transform CBD Oral Solid Dosage Systems

12/06/2019 Miami, FloridaImbucanna announced today the launch of the world’s first 75% concentrated directly compressible CBD. CBDC-75 effectively allows even the smallest of manufacturers to quickly formulate all sorts of CBD oral solid dosage (OSD) forms in one easy step, and with elementary formulation knowledge. The patent-pending granulates are a massive leap forward in CBD oral delivery technology, and alleviates the lack of content uniformity, use of solvents, production costs, and advanced formulation expertise needed to formulate regular tablets, chewables, ODTs, and other oral solid dosage forms of CBD.

“The introductory 75% directly compressible CBD powder can be easily dry mixed with the customer’s preferred filler-matrix, and compressed into strong orally disintegrating tablets (ODTs), chewables, mints, regular tablets, effervescent tablets, and other OSD forms of CBD with never before seen speed, ease, and low cost,” said Leo Mendez, Imbucanna’s Founder and CEO. “Our CBDC-75 is the first in a series of directly compressible cannabinoid intermediates created to take the guesswork out of formulating a portfolio of hemp-derived oral solid dosage forms.”

About Imbucanna:
Imbucanna is a pharmaceutical company that specializes in developing, producing, and marketing highly concentrated, hemp-derived intermediates for direct compression. The company provides over 30 different base CBD oral dose formulations for free on imbucanna.com.

Press Contacts:
Leo Mendez, CEO
Imbucanna.com
leo@imbucanna.com
201-744-5889

End


Jon Trauben: Choosing Smart Cannabis Investments

In our latest Q&A interview, we explore the background of Altitude Investment Management and hear directly from an investment professional about how to create a winning business plan and what it takes to get your fundraising efforts noticed in the cannabis space. Read the interview below to hear how investors approach the cannabis space, the benefits of investing in plant-touching businesses, and how to stand out in a crowd of “groundbreaking” cannabis business ideas.


Ganjapreneur: How long has Altitude Investment Management been operating in the cannabis industry, and what made the cannabis industry attractive from an investment standpoint?

Jon Trauben: Altitude was officially founded in 2017, but the partners have been investing in the regulated cannabis space since 2016 and saw an opportunity to bring professional institutional fund management to the industry. We knew cannabis had considerable investment potential for two reasons. We understood that the industry had a massive existing customer base both nationally and globally for this product, and we saw the opportunity to move that existing customer base through the legal channel and help it develop into a mature industry. At the same time, we saw the opportunity to participate in the early stages of that global opportunity while it is illiquid and inefficient because of prohibition and because it is still a start-up industry.

What background do the principals of Altitude have in the cannabis industry?

Since 2016, we have been fully and exclusively immersed in the cannabis industry by studying, analyzing, and investing across multiple verticals including plant-touching companies. The partners collectively bring to the table decades of experience in alternative asset, distressed, real estate and European investments through our prior careers. We make informed investment decisions and develop high conviction through deep analysis and research on opportunities and management teams and have successfully applied our skill sets to this industry and economic opportunity. 

We are also firm believers that the “fast money” trade-in cannabis is over and it has moved to “smart money” investing. The smart money investor finds the opportunity when the other capital is scared. Operating as a smart money investor means we have to have contacts, knowledge, and in-depth understanding of the industry to uncover the best-in-class opportunities.

For a startup or an established company, what are the benefits of working with an investment management firm for fundraising?

For a company looking to raise capital, a firm like Altitude can provide a broad-based footprint and contacts within the industry –both from the company’s standpoint and with other investors. The most lucrative benefit of working with a firm is getting traditional VC value-add which brings along money, relationships, and validation of their business strategy. Additionally, companies can gain access to personalized advice to help them grow, navigate issues, and, most importantly, receive guidance on liquidity and exit opportunities.

Why would investors prefer to work with investment management firms?

The regulated cannabis industry is very broad-based and complicated, but also very opaque. Unless you’re living in this industry 24/7 like we are, you simply don’t have the knowledge, context, or information flow to make educated and informed investment decisions. 

Our work in the industry has shown that the startup cycle is basically over in North America and we’re moving into the growth phase of the industry.  As such, the ability for individual investors to have any standing or clout at this phase has greatly diminished. Consequently, we see financing transactions revolving around lead investors that are fund vehicles that can use the power of their checkbook (i.e. the ability to write bigger checks and lead financings) to drive the best economic terms and attain the appropriate corporate involvement for its investment.  Previously in the start upcycle, companies were only raising $1-10 million and smaller investors were impactful. Nowadays, the individual investor that offers $50-250,000 just does not have the same value for a company is trying to raise $10- 50 million. We think it’s a continual reinforcement of access to funding driving the next leg of opportunity. 

Can you share an example of how Altitude has contributed to the success of a company in your portfolio?

A core part of our investment strategy is connecting our portfolio companies to customers and opportunities across the industry and setting them up to cross-pollinate within our portfolio holdings. Companies like to have Altitude as their lead and on their cap table because we help them to succeed in a number of ways and provide validation as we become an investor and bring along other capital to help them grow across the industry at large. 

We were able to execute this for our portfolio company PathogenDx, a cannabis and hemp pathogen testing company that uses patented DNA-based technology. We co-led their original round back in 2018 and now sit on the board of the company. They recently completed a subsequent financing of $7 million and we helped the company attract a lead investor and fill out the financing round. Our firm was able to assist the investors with their due diligence and analysis and we guided them through the process of acting as the lead. By being on the company’s board and having a bigger footprint in the industry, we had the ability to bring in a quality investor to the table to effectuate this capital raise. 

How does Altitude approach investing in plant-touching versus non-plant-touching businesses?

Initially, the Altitude partners were cautious of investing in plant-touching business due to prohibition.  However, after a thorough analysis of the risk profile, the partners got comfortable with those types of strategies. There is significant opportunity across the full spectrum of this industry, and plant-touching businesses are a primary and unique part of this market. From our own first-hand experience, we have seen that plant-touching companies are the leaders on the revenue side, as they are ultimately providing a product that the customer really wants. We have always believed that there are incredibly interesting and lucrative opportunities on the plant-touching side. In fact, two-thirds of our portfolio’s capital are invested in plant-touching companies. It’s our view that firms are missing out on a considerable industry opportunity if they’re not engaging with these types of companies.

What is the best way to submit a pitch, and what are some tips to stand out and be noticed in the pile of possible investments Altitude receives daily?

We’ve invested in 19 companies in the industry and we’ve reviewed over 1500, so the review process is highly selective and there’s a lot of due diligence in everything that we do. The companies that stand out the most provide a clear business proposal right off the bat and are realistic with their business strategy, revenue, performance projections, and valuation. We also want to learn how your product or service is specifically differentiated and if there is a defense against competition.

What qualities are you looking for when determining which companies to invest in?

At the top of the list is a qualified and experienced management team. We actively look for management teams with prior experience in the product and strategy they’re trying to execute and value individuals who take a mature and sober approach. Additionally, we appreciate company leaders who are candid about previous successes and failures in their business career because it shows how they have grown and learned from their prior experiences.

A lot of people also try to only pitch the positive aspects of their companies, but we appreciate when someone pitches the negatives and the challenges as well because it shows they understand what the issues are to their ability to execute. Demonstrating transparency and honesty is critical in this process. 

In 2019, you’ve expanded into Europe. What prompted that expansion? How has this experience differed from fundraising in North America?

We see a real opportunity in the rollout of European medical cannabis programs. Europe is several years behind North America in terms of its own legalization journey and we see an early opportunity to invest and support emerging vertically integrated and multi-jurisdictional operators in various European countries. Additionally, they are following a similar playbook in their enterprise value creation strategy that North American operators have developed. There’s a clear investment opportunity for us, and we are uniquely positioned to engage with this market. All of our partners have decades of experience investing in Europe, specifically our Partner Rod Stephan who lived and worked in both Zurich and London for 20 years. During that period, he led investment strategies for Citadel and my Partner John Brecker’s prior $3 billion hedge fund, Longacre Fund Management. He has a comprehensive understanding of the legal framework in Europe and also speaks fluent German. We also have a London-based strategic advisor and we recently opened an office in London which gives us a footprint and extensive industry network. We have the historical experience knowing how to invest in Europe, and we have the clout and presence to execute it. 

Another important aspect that differentiates us from our peers is that my three partners have decades of experience in investing in the distressed corporate world. The cannabis industry is undergoing a huge correction, and there are a number of companies coming out of this big start upcycle that are under a lot of balance sheet pressure and certainly there will be many failures. The ability to understand and navigate these distressed investment opportunities becomes a huge differentiator from our peers and positions us right in the middle of where many North American opportunities will lie.

The European cannabis opportunity has many similar attributes as the North American market, but there are also stark differences that we must accommodate for. One of the key differences is that medical cannabis programs are being sold through pharmacies and doctors instead of licensed dispensaries. This model brings different marketing challenges and it will develop into a different type of opportunity that will allow for less branding and marketing. However, the end opportunity could reap significant returns since consumers want legal access to safe, tested, quality products for health, wellness, and recreational purposes. The European industry may be developing differently, but demand is still robust and the medical market has become the market leader in the region.

What do you predict the next 5 years will look like for the cannabis industry on a global scale?

While we do not anticipate full federal or global legalization in the next five years, we predict a continued gradual relaxation of prohibition. Over time, that brings more capital and companies participating in the industry and a steady progress of cannabis legalization that usually start with medical programs, which are then followed by countries incrementally legalizing recreational programs.

In terms of long-term business opportunities, the industry’s supply chain needs to further develop and mature. We have not invested in pure-play cultivation since we believe that that strategy will face challenges of price compression and commoditization in the future. Where we have exposure to cultivation its via our investments in vertically integrated operators. Additionally, as the industry matures and professionalize, it pulls forward the services portion of the industry, and we anticipate continued opportunities for ancillary businesses in the coming years.


Thanks, Jon, for answering our questions and sharing your experiences from investing in the cannabis space! To learn more about Jon Trauben and/or Altitude Investment Management, visit AltitudeIn.com.

End


Hightimes Holding: ‘Substantial Doubt’ in Magazine’s Future

Hightimes Holding says there is “substantial doubt” about the company’s ability to continue operations in a Securities and Exchange Commission report by the firm outlined by the New York Post. The company says the uncertainty is due to “recurring operating losses, net operating cash flow deficits, and an accumulated deficit.”

In the report, Hightimes Holding had a net loss of $11.9 million on revenue of $10.7 million for the six months ending on June 30, 2019. The company has $105.2 million in debts.

In late October, the majority of DOPE Magazine’s Seattle editorial team was laid off by High Times – which acquired DOPE last year – and the office was shuttered. High Times CEO Kraig Fox called the move a “strategic decision” but noted that some employees had accepted positions at the company’s Los Angeles headquarters.

In addition to DOPE, High Times also purchased Green Rush Daily last year for $7 million and CULTURE magazine for $4 million.

The flurry of acquisitions came in conjunction with High Times’ Regulation A public offering – a new scheme that allows firms to sell shares directly to non-institution investors. The move followed the company’s plans to go public with an IPO, but that plan sputtered out. Regulation A is, essentially, crowdfunding that allows public offerings from companies in amounts of $50 million or less raised over one year.

The company has raised more than $15 million by more than 20,000 individual investors via the Reg A offering over a year after the funding was announced. Earlier this year, High Times Executive Chairman Adam Levin indicated the company was still seeking a NASDAQ listing but was also considering Canadian exchanges or over-the-counter (OTC) trading in the United States.

End


New Mexico Makes Third Hemp Industry Investment This Year

The New Mexico Economic Development Department is investing $200,000 in 420 Valley LLC, a Las Cruces-based hemp productions and processing plant, the agency announced on Wednesday. Officials say the commitment is part of plans to invest in sustainable agriculture and other economic sectors that can help diversify the state’s economy.

Gov. Lujan Grisham (D) said hemp and sustainable agriculture “are essential components” of the administration’s “mission to expand” the state’s economy. The funds will be distributed to 420 Valley over three years.

“We must think broader than one industry and one industry alone; we must create opportunity for New Mexico entrepreneurs and residents of all ages who are eager to find fulfilling work and launch sustainable careers. And through our Economic Development Department and other key initiatives we will do exactly that.” – Grisham, in a statement

420 Valley is a vertically integrated CBD products supplier, expected to hire 55 employees over three years who will earn an average salary of $33,000 per year, and the firm’s total payroll is expected to reach $2 million in three years. 420 Valley is set to begin hiring employees next year. The company has also signed an agreement to by a 13,000-square-foot building in Las Cruces, expecting to move in by January. 420 Valley Co-founder Rick Morales called the building “an eyesore” and the state investment will allow the firm to “make it usable and suitable.”

Las Cruces Mayor Ken Miyagishima said the business and state investment put the city “on the cusp of becoming a leader in growing a thriving industrial hemp industry.”

In May, the EDD pledged $2 million to Rich Global Hemp, which plans to hire 180 employees. In September, the agency dedicated $250,000 to New Mexico Hemp Services, a Santa Rosa-based industry job training business.

End


North Dakota Activists Submit Legalization Initiative Language to Officials

North Dakota activists have submitted the language for their ballot initiative to legalize cannabis for adults to the secretary of state for approval, the Bismarck Tribune reports. The secretary of state and state attorney general have one week to review the proposal and decide whether to approve the language in order for Legalize ND to move forward with collecting signatures.

The group would need to gather 13,452 valid signatures by July 6, 2020, to put the question to voters in the 2020 General Election.

David Owen, chairman of Legalize ND, told the Tribune that the organization hopes to gather more than 18,000 signatures to be on the safe side. North Dakota voters rejected adult-use legalization in 2018 by a majority of nearly 10 percent – 59 percent to 41 percent. That measure was reportedly rejected because it lacked rules and regulations and was poorly written. The measure submitted to officials this week was written by attorney Scott Brand, was sent twice to the Legislative Council, a nonpartisan legal and policy agency.

The measure would legalize use, purchase, and possession of up to 2 ounces of cannabis for adults 21-and-older. It would impose a 10 percent tax on cannabis products and does not include home-grow provisions.

Another group, ND for Freedom of Cannabis Act, is also seeking to put a legalization question to voters in 2020, but that plan would add legalization to the state constitution. That groups needs 26,904 signatures by February 10 – more than double the amount required by Legalize ND because it’s seeking to alter the constitution.

In other states that have posed potentially competing legalization initiatives, stakeholders expressed concerns that the dueling questions would prevent either measure from being approved.

End


Chris Hagedorn: Cultivation Supplies for the Cannabis Industry

Chris recently joined our podcast host TG Branfalt for an interview that ranges from broad entrepreneurialism to the latest federal cannabis policy developments. During their conversation, Chris discusses Hawthorne‘s status as a subsidiary of Ohio-based ScottsMiracle-Gro — the cultivation supplies powerhouse that has become a household brand throughout decades of success — and offers a unique look at his experiences coming from a more corporate environment at Scotts to the new and burgeoning cannabis space.

You can tune in to the latest Ganjapreneur.com podcast episode below, or scroll further down to find a full transcript of the interview.


Listen to the podcast:


Read the transcript:

Commercial: This episode of the Ganjapreneur podcast is made possible by 420-friendly service providers in the Ganjapreneur business directory. If you need professional help with your business, from accounting, to legal services, to consulting, marketing, payment processing, or insurance, visit Ganjapreneur.com slash businesses to find service providers who specialize in helping cannabis entrepreneurs like you. Visit the Ganjapreneur business directory today at Ganjapreneur.com/businesses.

TG Branfalt: Hey there. I’m your host, TG Branfalt and thank you for listening to the Ganjapreneur.com podcast where we try to bring you actionable information and normalize cannabis through the stories of Ganjapreneurs, activists, and industry stakeholders.

Today I’m joined by Chris Hagedorn. He’s the general manager for Vancouver, Washington-based Hawthorne Gardening, which provides cultivation supplies. He’s been a featured speaker at MJBizCon, and has been in his role with Hawthorne since 2014. How are you doing today, Chris?

Chris Hagedorn: I’m doing all right, man. How about yourself?

TG Branfalt: Never a bad day, man. Never a bad day. It’s nice to have you on. I admittedly, and I’ve said this on the show several times, I’ve never even grown a sunflower. It’s nice to have people on that can fill in these big gaps that I have in my own knowledge base and help to inform our listeners.

Before we get into some of the details of what you do, tell me about yourself. How’d you end up in the cannabis space?

Chris Hagedorn: Sure, yes. So grew up around the gardening business. My grandpa actually, Horace, started Miracle Grow back in the fifties here in New York, which is where I’m at currently. So grew up around the business. My old man, Jim, took it over in the mid-90’s. So always been around growing plants.

When I was getting out of college, getting married and all that, started looking at the business. Me, my father, our board of directors and everyone saw what looked like a big opportunity. So we started looking around and it’s always something that we’ve been personally, as a family, kind of passionate about, both the recreational and therapeutic medical side. It was personal passion and business interest aligned and just super lucky to be here at this time. This window opened that we were able to throw ourselves through.

TG Branfalt: You’re in New York right now. Are you in New York City?

Chris Hagedorn: No, no. I’m on Long Island, a town called Port Washington.

TG Branfalt: All right. I’m also in New York. I live in the Adirondacks. This coming session it’s looking like we might actually get legalization. The industry you’re in, are you guys expecting that? What’s sort of the hubbub within the industry in New York?

Chris Hagedorn: So look, we’re certainly hopeful. We try to stay pretty active when it comes to government relations. Look, it’s a prettier word for lobbying, which always kind of had a negative connotation to me, until I got into a business where it felt pretty necessary to help steer politicians and legislators who might not be super informed about this industry, to make sensible decisions for their constituents, for the voters.

We’re hopeful. But again, look I was hopeful last time this thing came up, and we got stymied by law enforcement and Mothers Against Drunk Driving, a lot of people who I think are well intentioned but maybe not super well informed about the industry, about the product. So again, I’m cautiously optimistic but I don’t think I can go much further than that.

TG Branfalt: Well in Long Island, we have sort of the strange democrats down there that don’t often support medical cannabis. In upstate New York, that’s obviously the same deal, is that they don’t support cannabis policy. Anyway, we sort of went off on a tangent there.

Tell me what sets Hawthorne apart from other picks-and-shovels companies in the cannabis industry.

Chris Hagedorn: I think the biggest thing that sets us apart is we really look at the grow, whether you’re talking about a small basement grow, like a ten lighter, or a big indoor grow, a greenhouse, or even outdoor. Then we look at everything pretty holistically. We don’t have a lot of people that compete against us in every single category that we’re in.

I think when you look at lights and nutrients, growing media, air handling and filtration, kind of H fax stuff, control systems, that we really look at it all in a way that I’m not sure a lot of other people do. Which I think you need to when everything needs to work together.

TG Branfalt: When you talk about the nutrients and all of the stuff that you offer, what’s the learning curve there applying that to cannabis for you and for the consumers that you might come across?

Chris Hagedorn: Sure, yeah. Look, I think there’s a pretty steep learning curve when it comes to growing this plant. It’s a plant and I think the vast majority of plants share a whole bunch of different attributes that are fairly common across the board. Every plant needs light, every plant needs water and nutrients and all that.

But this is a really, really complex plant. We’ve certainly learned. Scott’s is a company that’s been around. So just a little background, Scott’s and Miracle Grow merged back in 1995. Miracle Grow was my family’s business. Scott’s had already existed. So combined, the business has existed for over 150 years. We’ve been growing plants that whole time. So we felt like we had a pretty good grasp on how this whole thing worked.

It’s been a real learning experience for us over the past five, six years that we’ve been entered the category, just learning how much complexity there is to the plant, how many different ways you can push it to do different things. And frankly, that’s something we’re hoping to learn even more about. We’re building an R&D facility up in Canada right now so we can do real research on the plant we can’t do here in the US.

So I think the learning curve is steep and we haven’t reached the top of it or bottom of it, however you want to look at it, yet. And won’t for some time.

TG Branfalt: Miracle Grow, that’s a household name. I guess the question is, what was the internal decision making that went on when you guys decided to enter this space?

Chris Hagedorn: We’ve been looking at cannabis for quite a while. I think my old man is first sort of recorded saying something in a Wall Street Journal article back in like, 2011. He was asked by the interviewer, “Is this something you guys are looking at?” And he said, “Yeah. Look, it’s people growing plants. There’s no reason we wouldn’t.”

At the time, our Board of Directors and a lot of our investors flipped out and were super uncomfortable with the idea. So it took a few more years for us to kind of get over the hump with people, to show them it was a worthwhile initiative for us and a worthwhile strategy. Once we got over that hump, there was still a bit of testing the water where we were saying, “Okay, we’ll buy a nutrient brand.” Because we know plant food. Before something like lights, which we did subsequently.

TG Branfalt: Since 2014, you guys have added general hydroponics, botanic care, Gavina horticulture lighting to the portfolio. What do you guys look for in potential brands?

Chris Hagedorn: Yeah. We look for brands that … There’s a lot of brands across the hydro category that are what I would consider sort of less clean, and I’m talking about some sort of a brand identity perspective. Some brands that advertise it’s all about weed, it’s all about women shoving big buds into their cleavage and stuff, which is fine, whatever. I don’t mean to sound judgey.

TG Branfalt: No, you see that a lot at trade shows.

Chris Hagedorn: Oh yeah. No, it’s all over the place. I think for a while, it had been kind of the standard way you portrayed yourself. Obviously, that’s not something that we really identify with as a company. So we’re looking for people who market themselves more about just the product.

How is the product? How does it work? What can it do for a grower? We also look for brands that are market leaders, brands that have really good position in the marketplace, brands that have really unique, high quality products. Brands that have good management teams. Because going into this, we knew that we needed people who really understood hydro, who understood cannabis in a way that we didn’t, just because we were new.

We looked pretty hard at who the folks were that actually made up these companies. Obviously in concert with the brands that they were pushing to make sure that it was a good fit for us.

TG Branfalt: Obviously, Scott’s Miracle Grow, as I said it’s a household name. I actually covered a few years ago a story with Scott’s, and I found it interesting reading the comments, which I don’t do anymore, how many people were upset with Scott’s getting into the cannabis space, buying up some of these companies. What is your reaction to those who people moan the entrée of companies like Scott’s into the cannabis space?

Chris Hagedorn: Look, I get it. I think a lot of people really loved the cottage industry that cannabis was, that it had developed into over the years. I get that. I don’t begrudge them hanging on to that past.

The reality is, this industry is evolving, and it’s coming out of the shadows. It’s coming into the spotlight. I think there’s a few things that people should look at when it comes to a company like ours being in the category. Which is number one, Scott’s, if you look across the landscape at other cannabis companies, we are not the big guys in a room anymore. We’ve got customers that we work with up in Canada, like Canopy Growth Corporation, who have twice the market cap that Scott’s does.

I don’t really think of us as the big guy anymore. But I think a lot of people just don’t like the idea of what they consider corporate America coming into the space. Again, I get it. On the other hand, I see the benefit. Which for us is, look, you got guys who are growing really fast. Customers of ours, whether those are retailers, or the folks that they sell to, the growers, who are growing 100% a year and moving into new states all the time, or new countries across the world. Those guys need a company who can supply them with equipment that can scale as quickly as they are. That’s something I think we’re pretty uniquely positioned to do, just with the infrastructure Scott’s has. We can actually serve customers globally, in a way that I don’t think a lot of the folks we compete with can.

I see us as a necessary part of the evolution. This is going big time. We’ve been part of big American business for a while, and I think it was a union that was just bound to happen. I hope that people can look at our actions since we’ve been here and assess us fairly for who we’ve proven ourselves to be, not who they assumed us to be.

TG Branfalt: You said that you do some political outreach, the sort of soft term for lobbying. Not a lot of companies I don’t think are in that position to do that. In that role, where do you see yourself in that role? Do you see yourself as sort of the household name that’s going to bat for this industry? What’s that relationship evolved to? What’s it like?

Chris Hagedorn: I do see us having some role. I hesitate to say that too strongly, because I think it could come off as condescending to the industry. The industry has plenty of advocates. There’s plenty of folks down in DC and all across the country that are, excuse me, I’ve got a little bit of a cold I’m getting over, who are pushing hard for this industry, and pushing hard to protect consumers and protect growers and retailers and everyone else.

But I think we are seen by some folks in the government as sort of the adults in the room. Right or wrong, just because we’re a big, publicly traded company from Ohio. So they feel like when we show up that we have a maturity. So again, whether that’s a legitimate perspective that we’ve earned and that other people should be seen as immature, I’m not going to even get in to all that.

But I think for legislators who don’t know any better, they see us as being kind of the mature folks in the room. I think when we say something, it carries gravity that it might not have when it comes from some other people, even if it should. So we try to use that perceived weight for good.

Now look, obviously we want to steer things in a way that’s beneficial to ourselves along with the rest of the industry. But I think again, I think we’ve got an ability to make our voice heard in a way that I think a lot of other folks in the industry, no matter how legit it is what they’re saying, they might not have that ability.

TG Branfalt: What has been your experience with companies that are specifically focused on growing cannabis? Are they hesitant to work with you due to your corporate ties and your publicly traded status?

Chris Hagedorn: We’ve caught some folks that have not been happy with us, some folks that haven’t wanted to work with us. We’ve encountered a heck of a lot more people that have wanted to work with us, who see our scale, our ability to service them really efficiently, as a benefit.

It’s something that I think we definitely dealt with more the first couple years we entered the category where people really didn’t know what to think of us, just saw us as kind of big guys who were pushing our way into the space. That perception I think has fallen off due to the work that the team out there working with retailers, working with growers. The work that they have done I think has really … turned down that negative opinion.

But look, there’s still some folks out there that are skeptical, who’d rather work with small craft brands, and I get that. Look, as a consumer, I enjoy drinking craft beer, smoking craft cannabis. So I understand the tendency towards smaller brands. But it’s something that we’ve dealt with less and less.

TG Branfalt: You said in an interview that you see greenhouse growing, becoming “the most prevalent form of growing” cannabis, I presume. How is your company preparing for that change?

Chris Hagedorn: We’re developing all sorts of products right now, from lights to nutrients and air movement products, and HVAC products specifically designed for greenhouse, which I still believe is completely inevitable.

We sell a heck of a lot of lights that are used primarily for indoor. But products like the Gavita, the standard Gavita 1000 watt HPS light that’s a high pressure sodium light, that’s a product that was developed in Holland for traditional greenhouse growing. It’s a supplemental top light. So the products in our portfolio, the heritage that we have, is really built around greenhouse growing. And it’s just so much more energy efficient. When you look at what I think is going to be a real reckoning when it comes to sustainability, just the way that cannabis is grown right now, it’s a pretty unsustainable process, when you think environmentally.

So I think there’s going to be, either the industry is going to start to hold itself to a higher standard, which we hope to be a part of, or the government is going to come in and tell us, “You’re going to have to grow a different way.” And we want to be prepared for that.

Because look, the reality is, you can get extremely high quality flower out of a greenhouse with a fraction of the energy consumption, just by using the sun, instead of buying all of our lights. Look, don’t get me wrong, I love selling lights, but I look at the large reality and just our business performance as, we’ve got to figure out a way to do this more efficiently.

Like I said, we’re developing LED lights designed for use as a supplement to light in greenhouse. We’re looking at different nutrient packages that are as efficient as possible for the consumer from a cost perspective. So we got a bunch of stuff we’re working from an innovation perspective. Like I said, that facility we’re working on up in Canada is going to allow us to really get creative with how the plant is cultivated, and I think learn some pretty interesting stuff. Just because I don’t think a lot of the research that we plan to conduct up there is being done right now in as rigorous a setting as we’ll conduct it.

TG Branfalt: Can you tell me more about what you’re doing up in Canada? I’m very interested in the … talking about very specific sort of things, but you’re talking about them vaguely.

Chris Hagedorn: Yeah, sure. Which is not entirely by accident.

TG Branfalt: Yeah. No, for sure. I get it.

Chris Hagedorn: We’ve been launching products and the brands that we’ve acquired have been launching products forever, that they’re designed and the intent is for them to work well on cannabis. But the reality is that we didn’t really know. We’d test them on what we call proxy crops. We test them on petunias, test them on tomatoes.

Again, you look at it and say, “Okay, we’re pretty sure this is going to work well.” Back in the day, before we acquired these businesses, maybe they’d give some to a sales guy who is growing in his house. And you say, “Hey, let us know how it went. Let us know what the effect was.” For me, that’s not good enough.

When I look at my counter pot parts at Scott’s Miracle Grow in Ohio, who are launching for example like a rose plant food, the idea that they would launch that without having tested it on roses is completely ridiculous. So for us, it was essential that we have the ability to actually test our products on the plant that a lot of our consumers will be growing. So we couldn’t do that here in the US just due to the federal law and all the restrictions we have. So we went to Canada and we’re building out a 50,000 square foot facility up in Canada that will be a combination of indoor, outdoor and greenhouse, with the intent of really getting smart on how do all our products work on the plant?

Again, we know they work because people buy them and people give us feedback, so we feel pretty confident. But I want to know how our products stack up against our competition really. I believe our products are the best, but I want to be able to run really rigorous, stringent side by side testing. And then I want to innovate. I want to know if I shine a certain spectrum of light on the plant at certain times and give it certain types of nutrients and certain trace minerals, what can we do with the plant? Can I drive a plant to create way more CBD or THC or some other compound? Can I cause the plant to put out a different terpene profile than it would otherwise?

Those are all things that we haven’t had the ability to do yet, and I don’t see a lot of, what I would consider scientifically rigorous testing being done in the space yet. I have no doubt that it will be done soon, and I’m sure lots of people are working on it. But this is going to be a purpose-built facility to really show us what our products do and how can we make them even better?

TG Branfalt: Is this your baby, man? Because you sound really, really passionate about it.

Chris Hagedorn: Yeah. At the risk of sounding selfish, and look, I have done the Hawthorne thing with my pops and I’ll spare the language partially. My father is a pretty colorful guy when it comes to language. We’ll put proposal in front of him and he’ll say, “Yeah, you and what effing army?”

Look, I’ve had an army with me on this. It’s been the opposite of doing this alone. So I’ve got hundreds and hundreds of people who have been part of it and we’ve spent a ton of Scott’s Miracle Grow money to get it done. But this Hawthorne thing I do see as my, along with a lot of other people’s babies. It’s something I care a lot about.

And this Canadian thing is just … It’s not going to be the crown jewel in it. I think the Sunlight acquisition that we did 14, 15 months ago, that was the crown jewel up to this point. But this Canadian thing, it’s so important. It’s such a common sense move for us, and it took a lot of maneuvering within the bureaucracy of Scott’s to get it approved. Because it’s not an insignificant amount of money we have to invest up there. It took a lot of searching to find the right partner. We needed someone who was a licensed grower up in Canada, an operating LP because we needed to piggyback on that license. So it was a long, complicated process to get where we’re at, and we should be opening that facility in the next few months. So I am passionate and yeah, I’m really excited.

TG Branfalt: One of the I think overlooked issues, and when we talk about cannabis cultivation, legally is something you alluded to earlier, was the electricity aspect of it. Part of that is due to local governments, right? Some states do not allow outdoor cultivation full stop in more conservative states. How long until, in your estimation, until we see a change to more efficient ways of growing nationwide?

Chris Hagedorn: I think to get to a really efficient place nationwide is going to necessitate federal legalization. Having every state be its own little kind of micro market where you can’t move product across state lines, at least not cannabis, obviously hemp is a different story. But for cannabis, it’s going to be a little weird. Because a place like where you live, it’s like there’s not a whole lot of growing season out there. You can get like one turn in and that’s just not going to cut it for most people.

To say nothing of most places like Maine or Vermont or New Hampshire, New England or the Pac Northwest, whatever. So a lot of parts of the country you got to grow indoors. Greenhouse works a little bit better. But again, I think to really move towards truly efficient growing is going to demand 50-state legalization and the ability to move product across state lines.

Although to be candid, that’s not a … so I’m going to sound like I’m kind of going against what I just said, but I’m not really looking forward to 50-state legalization. For us, that’s a tough day, just because every new market being its own unique market in each state, that means that every new state that gets legalized, there’s a bunch of new grows, we sell a bunch of new product as spots get built out. So we like this kind of steady, a couple states every year marks that we’ve been on for the past few years because it just ensures really good business for us.

That’s one of the things that worries me, as much excitement as there is about 50-state legalization, when that happens, it’s only a matter of time before we move towards these super farms that are going to be really low cost, they’ll move product all over the country. It’s going to change the industry in ways that I don’t think anybody can really anticipate. It’s something that scares me as a business person. It scares me as a consumer, as just a fan of the category, a fan of the industry. It’s going to have ripple effects that I don’t think anyone can really predict.

TG Branfalt: Not for nothing, it’s sort of unexpected to hear you speaking out against super farms and a monopolization of cannabis considering these are the same thing that people are saying about your own company, that they’re worried about.

Chris Hagedorn: Fair enough. I don’t know if I’m blurring the lines too much of sort of, me the individual and me the business person. What I would say is look, we don’t hold such dominant market share in any category that I would consider us even close to monopolization. We got dozens and dozens of strong competitors in every category.

I’m glad for that. It makes us better. It keeps us sharper. It makes us fight harder. As for my concern about large grows dominating this industry, from a purely practical perspective, it’s not a good thing for my business. That’s the reality. You’re going to find people who are going to be extremely bottom line focused, which business people should be. But they are going to be growing things as cheaply as possible which means it’s going to make life harder for me and everyone else.

Now look, the benefit will be for the consumer, but I think it’s going to be potentially a little harder to find really good quality product. We’ll move towards that kind of Budweiser world where yeah, you can get Bud anywhere, but is that really what you’re looking for?

Again, I’m blending the lines a little bit between I don’t think it’s a great thing for my business. And we’re preparing for that world obviously, we know it’s just a matter of time. I think we’ll be as well positioned as anybody to deal with it. But it’s not something I relish. As a consumer, as a cannabis consumer, cannabis fan, yeah, it’s not something I’m super excited about because I think it’s going to put some small growers out of business that just sucks to see. It’s going to make mass grown, mid quality flower way more prevalent, which I’m not ultra excited about either.

Again, I apologize to the skeptics who are listening that I’m maybe contradicting myself or sounding hypocritical, but that is the way I feel.

TG Branfalt: No, I mean I’ve said plenty of times on this show like I’m pro legalization, just not really looking forward to the day where it’s federally legal. I think that it’s going to create a lot of problems for the smaller growers. I think it’s going to marginalize far more people, maybe not than the drug war did, I mean I think that’s a little hyperbolic.

But the people who have sort of made something for themself in the sort of nascent industry, I think it’s going to crush them. I’ve been saying that for quite a while. But I want to talk more about the R&D stuff. I know that you can’t say too much about the Canadian stuff and I can’t wait to hear more about that when it’s up and running.

But what do you think is the most pressing issue for cultivation focused companies with regard to research and development as the cannabis industry explodes?

Chris Hagedorn: I think there’s a few issues that people need to be addressing. People are doing it all in their own ways. I think to me, the biggest one was doing work on the actual plant. Which again, we’ve talked at some length about that, and at least the technique we took to get around that issue here in the US, which is go to Canada.

But I think you look at some other issues, and obviously these are sort of front of mind for me. But all this kind of scare right now around vaping I think is a huge issue. I think there’s like no actual understanding of what’s going on. A lot of people are making assumptions and saying, “This is what the problem is,” or, “That’s what the problem is.” I don’t think anyone knows. And we’re working our butts off right now to try to figure out what the cause is, or at least eliminate things we know aren’t the cause, which maybe is a more efficient way to get to it.

But I think really understanding, look, the things that we put into this plant, when you light it on fire and inhale it or put it through an extraction machine and you concentrate stuff, things happen to the chemicals that go into these plants, whether you’re growing organically or not. So for people to really understand, how do the things that I put into soil or in my nutrient reservoirs or a foliar spray that I spray on my plants, how do those things end up or not end up in consumers and what is the effect there? That’s a really important thing to understand, just from a consumer safety standpoint.

Especially when you think about the fact that, look, a lot of this is sold to people who we call patients. Sold to people who are sick or who need this for their wellness in one regard or another, either mental or physical. If we, and when I say we, I mean the industry as a whole, are giving people product that we don’t know how it might effect them, it’s just irresponsible.

Again, we do every bit of work we possibly can to feel comfortable with what we sell. And if we can’t get comfortable, the bottom line is we just don’t sell it. I don’t mean to make accusations, but I’m not sure the entire industry holds itself to that standard. I think it’s something that it’s concerning to me, and I think people need to start taking a hard look at what’s in their portfolio and how much do we really know about it?

TG Branfalt: To your point, there’s not a day that … I come to this industry daily, and there’s really not a day that goes by where there’s not some sort of lawsuit alleging bad behavior. A couple companies in Canada just got their licenses suspended, and the pesticide issue. I think part of the way that we … why do you use vape cartridges? Because you can do it clandestine.

Chris Hagedorn: Yeah, the discretion, yeah.

TG Branfalt: We haven’t had these sort of … no one died of lung illness related to just smoking cannabis. It’s just sort of to your point, about the potential for bad by some bad actors looking at the bottom line. You’re really a breath of fresh air that I wasn’t expecting, Chris.

Now your company is based in Washington, which is one of the more mature markets in the United States. What do you see in Washington that’s becoming the pressing issue there, or some of the changes that might be coming down the pipe for the industry?

Chris Hagedorn: Washington is a unique state. Look, every state is unique right now, and that’s part of the frustration for someone in my position. Every state is trying to reinvent the wheel when it comes to regulation and legislation and the way this is all rolled out.

Which is frustrating because they don’t need to do that. There are states that have figured it out. Well maybe not all the way, but states that have made mistakes and fixed them. It’s frustrating to see other states make those same mistakes again.

As for Washington, look I think the biggest thing, and anybody who is in Washington, and I think Oregon went through the same thing about a year ago was, those states didn’t take a very strict approach when it came to capping the number of growers. They didn’t take any approach, frankly. If you had a checking account with 500 bucks in it, and a pencil, you could fill out that application, write the check, and you were good to go as a grower. And I think that called a lot of people to rush into those states from other areas and try to stake their claim as a cannabis grower, as a marijuana millionaire.

So you saw those markets get flooded with product and it just completely tanked the price of actual flower and extract and everything. I remember reading a thing, I think it was Oregon not Washington, but these problems I think exist in both states, at least they did a year ago, where there was a back log of product that was … it was like five pounds for every man, woman, and child in the state.

TG Branfalt: It last them like two years or something.

Chris Hagedorn: Exactly. So stuff like that is crazy and I think it’s … I just said the reasons that I like the state by state rollout, but this that we’re talking about right now, this is one of the downsides is, you can end up with crazy over supply and it really jacks the pricing up and it makes it hard for anybody to make money. Maybe the dispensaries can make some money, even though I think that’s pretty difficult with the way that they’re taxed, the way they have to bank right now.

I know that improved pretty recently with the Safe Banking Act. Looking like it’s making progress. When you end up with anybody that can come in and grow, there’s not really a cap on how many they’ll be or how much they can grow, you’re going to end up with people in a relatively immature industry where people aren’t thinking about, “Does this state market need another grower?” People just show up and start growing and you end up with a lot of supply that outstrips demand, it screws pricing up, and it takes a long time to recover that.

Look, the silver lining here is that this product does have a shelf life. You can’t just sit in your warehouse for five years look you could a bottle of wine. It does eventually go bad. It sucks for growers that end up having to sit on stuff until it goes bad, but it does reset the marketplace in a way that I think is healthy for business.

TG Branfalt: Can I ask, since federal legalization in Canada, how much did that increase your footprint in Canada, your business in Canada?

Chris Hagedorn: A lot, I’d say, to say it broadly. We don’t have the same restrictions in Canada that we do here. Down here … it’s really interesting. It’s two very different marketplaces.

Here in the US, there’s a network of more than 2000 hydroponic retailers. These are just your neighborhood hydro shop. Those guys have been a integral part of this whole process for decades now. It’s the place that growers went to for advice, for a tip on some new product or some new technique, and they’ve really become a structural part of the industry.

Up in Canada, there wasn’t really the same network or retailers, which opened the door for a company like us to deal directly with the growers up there. We didn’t have any laws up there. We didn’t have any bankers that we work with telling us we couldn’t do it. So we just went directly to the LPs and started transacting directly with them. It’s great for us. I think it’s good for our customers up there. It keeps prices down. It keeps margins healthy, and it allows us to really learn how to work with large scale growers.

Now here in the US, I don’t see things becoming the way they are up in Canada for quite a while, frankly if ever. Just because these retailers have made themselves so indispensable. But for us, knowing how to service people with a lot of different facilities across a really wide geographic area, people who are … we’re dealing with growers up there who’ve got entire purchasing departments and procurement teams. You’re dealing with much more of a corporation customer than you are an individual like you are down here.

I think it’s been really valuable learning for us because there’s going to come a time where that’s going to be just the way it is everywhere. And for us to be able to cut our teeth up in Canada is really useful because Canada is smaller than California when it comes to population, when it comes to the total market for us. So it’s a good rehearsal, I’d say.

TG Branfalt: As general manager, how hands on are you with these sort of international deals?

Chris Hagedorn: It depends. Every one of these relationships is unique. We do try to treat … you know it’s interesting. Like I said, the US and Canada are very different marketplaces and environments for us. So I’d say our large customers up in Canada are the growers. Our largest customers down here are large retailers.

You’re starting to see more and more retailers that are chains that have multiple stores, either in the same state or across the country. We try to treat all those guys kind of the same. And this is something that we learned from our brethren back in Ohio at Scott’s Miracle Grow is, you establish what we call top of the top relationships, which is how they deal with their big customers, guys like Home Depot or Lowe’s.

Where they’ll, every quarter, so four times a year, the leadership at Scott’s will meet with the leadership at Home Depot and have dinner and catch up and talk about any outstanding issues, that kind of thing. That’s been the kind of relationship that we try to forge with our customers, our bigger customers. Again, up in Canada, as growers, down here as retailers, is to really try to get a good personal connection at the top.

Day to day, the relationships are serviced by our sales professionals, by our customer service people, et cetera. But again, we try to have the top of the top relationship that at least if I reach out to the CEO of a big grow up in Canada, or the CEO of a big retailer here, that I’ve got them in my phone, that they’ll respond to me and vice versa. That personal touch is still super important.

I can’t do it everywhere. We just have too many customers at this point. But for the big folks, yeah, it’s … and this is true of any industry, that the personal touch, especially from leadership, just goes a heck of a long way.

I’m lucky. I’ve mentioned at the top of the pod about how important it was for us to buy businesses that have strong management teams. We’ve been able to retain a lot of the top talent from the businesses that we’ve bought, and that really lightens the load for me, just because we got a lot of people who know this industry, who’ve got a ton of great relationships. And who are, not just trusted by me, but I think trusted by our customers also.

TG Branfalt: Man, I really appreciate your candor on this. It’s really not everyday that I have this opportunity to really pick the brain of somebody who operates internationally for this very well known company. Your passion just comes through and like I said, it’s refreshing to hear that.

Chris Hagedorn: Thank you.

TG Branfalt: What advice do you have or would you have for entrepreneurs? You deal with a lot of people, individuals and otherwise. What advice do you have for entrepreneurs who are looking to enter the space?

Chris Hagedorn: I’d say look, you’ve got to be super determined. I’m going to be, in the interest of trying to stay as candid and transparent as I can, I can’t speak to some of the struggles that I think your average entrepreneur is going to have because I was born into this. So I didn’t have to fight a lot of the battles that I think a lot of the folks that we’ll be talking to right now will have to fight. That’s just the reality.

I wish for my own sense of pride and ego that I could say I’d fought those battles, but I’m super lucky. I’ve been given opportunities that I’ve tried really hard not to screw up and I think I’ve done okay. But again, I haven’t been the guy scrapping and bootstrapping for funding. I never had to do that.

I’m going to be talking a little out of turn here, just my perspective for whatever it’s worth. Look, do not get discouraged. It’s going to be a long, hard battle. Don’t over promise. If you’re bringing money on from investors, whether that’s … and especially if it’s friends and family, don’t tell them fairytales about what you’ll be able to deliver or when. You’ve got to start by being honest with yourself. And then you got to be honest with the folks who are helping you do it that, it’s going to take a while.

There’s a really real chance it won’t work. Just like in any business. But I think especially this one. It’s really competitive. I’ve said this a lot of times, I think this is the hottest, most exciting industry I guess outside of tech, Silicon Valley shit, in the entire world, certainly in America. I don’t know how to code, so this is kind of it for me. This is something I care about.

But there’s a lot of people that are attacking this industry right now, a lot of people that are trying to make moves in it. So it’s a crowded marketplace right now with a lot of people coming after the same opportunities. And Silicon Valley doesn’t deal with the same stuff that we deal with here, which is a ridiculous tax code where people are getting taxed like 80% because they can’t deduct normal business expenses. Silicon Valley can get banking relationships that most of our customers can’t.

It’s a hard place to make money right now in America. I think if you can establish a business and weather the storm in terms of taxation and banking and everything else, and actually stick around until those laws rationalize, and they will eventually, I think you’ll be sitting on a cash machine. But until then, it’s going to be hard. I just think a lot of people come into this industry expecting, “If I grow weed, people will buy it and I’ll make a lot of money.” That’s not the way it is. It’s a lot harder than people seem to think before they enter it.

So I’d say again, do not lose hope, but don’t lie to yourself and certainly don’t lie to the people that are investing in you, because it’s hard. I’ve seen a lot of people who have worked their asses off who have been very smart people kind of lose everything they put into it just because it’s difficult. So I’m repeating myself now.

TG Branfalt: Where can people find out more about you, more about Hawthorne? Plug it up, man.

Chris Hagedorn: Oh god, okay. So look, go to our website HawthorneGC.com. We tried to buy Hawthorne but it belongs to some company that sells like Christmas ornaments and they wouldn’t sell it to us for what I would consider a reasonable price, so HawthorneGC.com was as close as we could get. So go check that out. Check out all our social, Hawthorne gardening on Instagram and all that.

As for me, type my name into Google. Stuff about me is out there. Please just do your research. I’ve had a lot of people who’ve read some, what I would consider a biased post on like Facebook, written by our detractors who assume that they know everything that there is to know about me. I’ve done enough of these kind of interviews and stuff. Just look around and do your research and get what I would hope would be a balanced perspective. Just because there’s a lot of nonsense out there. We’ve already talked about on this.

TG Branfalt: Yeah. It’s the Internet. There’s a lot of nonsense everywhere.

Chris Hagedorn: Yeah.

TG Branfalt: So I want to thank you, man. This has been a lot of fun. I’m really, really excited about this Canada thing, so I hope that you can keep me in the loop somewhat on that.

Chris Hagedorn: Yeah. Maybe we can do a follow up pod from Kelowna.

TG Branfalt: Or we can just go to Canada.

Chris Hagedorn: Yeah that sounds good. Yeah exactly, we’ll hop on the plane and fly up there and…

TG Branfalt: I live an hour from the border. I’ll just walk over.

Chris Hagedorn: All right. Fair enough, yeah. We’ll meet you up there, then.

TG Branfalt: My guest was Chris Hagedorn. He’s the general manager for Vancouver, Washington based Hawthorne Gardening. I think your grandfather would be quite proud of you, man. I really appreciate you taking the time to come on the show.

Chris Hagedorn: Thank you, man. I appreciate you saying that. It’s been a lot of fun.

TG Branfalt: You can find more episodes of the Ganjapreneur.com podcast in the podcast section of Ganjapreneur.com and in the Apple iTunes store. On the Ganjapreneur.com website, you will find the latest cannabis news and cannabis jobs updated daily, along with transcripts of this podcast.

You can also download the Ganjapreneur.com app at iTunes and Google Play. This episode was engineered by Trim Media House. I’ve been your host, TG Branfalt.

End


New Zealand to Put Legalization Question to Voters

New Zealand has announced there will be a nationwide referendum on cannabis legalization and the government outlined their legalization plan, setting the purchase age at 20, a purchase limit of 14 grams per day, and home-grow limits of two plants per person or four plants per household.

If the referendum is approved, it would require Parliament to approve sweeping legalization reforms.

According to policy documents, the bill would “disempower gangs,” lower the prison population, especially for the indigenous Māori population, and lower youth cannabis-use rates through education programs.

Following her election, Prime Minister Jacinda Ardern indicated she would put the issue to voters.

“During the campaign I’ve always been very vocal about the fact that I do not believe people should be imprisoned for the personal use of cannabis. On the flip-side, I also have concerns around young people accessing a product which can clearly do harm and damage to them.” – Ardern, to CNBC, Oct. 19, 2017

The plan includes a progressive excise tax, based on THC, similar to the nation’s tax scheme on alcohol.

The government notes that there are currently plans underway to expand the nation’s medical cannabis program to include a wider variety of products; rules for the expansion are expected this month.

A 2018 poll found 46 percent of New Zealanders supported legalization, with 41 percent opposed.

If approved, New Zealand would join Uruguay and Canada with federally-approved cannabis markets.

End


New Hampshire Cannabis Legalization Push Stalls In Senate

A bill to legalize cannabis for adult use in New Hampshire appears to have lost its momentum in the state Senate, where lawmakers in the Senate Judiciary Committee voted unanimously to kick the proposal to interim study, effectively killing the state’s 2020 legalization hopes, New Hampshire Public Radio reports.

The bill, which was approved earlier this year by the House, would have allowed for the adult possession of up to 28 grams of cannabis flower and the home growing of up to six cannabis plants; the bill also aimed to establish a regulatory committee to create rules and regulations for a legal cannabis industry and would have set a cannabis excise tax at 9 percent.

Senators also rejected a bill that would have let doctors make medical cannabis recommendations for “any condition.”

In New Hampshire, Democrats control both the House and Senate, though Republican Gov. Chris Sununu has already said he would veto any adult-use cannabis reforms that reach his desk — the governor, however, did sign a decriminalization bill into law in 2017.

New Hampshire is surrounded on all sides by legal cannabis markets, including Maine, Massachusetts, Vermont, and Canada. Meanwhile, nearby New York is expected to make a strong legalization push in 2020.

End


Virginia AG Hosting Cannabis Summit

Virginia Attorney General Mark Herring and the Virginia Cannabis Caucus – a group of pro-legalization lawmakers – are hosting a Cannabis Summit next week to discuss the state’s policies including recreational legalization, hemp, law enforcement, and social equity.

The summit will be held just over two months after Herring tweeted support for legalization which linked to a University of Mary Washington poll that found 61 percent of Virginians supported the reforms. In a June op-ed in the Daily Press, Herring said prohibition “is needlessly creating criminals and burdening Virginians with convictions” and called for broad decriminalization.

Last year, legislative committees in both the House and Senate killed two decriminalization bills. Those bills were supported by the Northam administration but the Virginia Association of Commonwealth Attorneys stood opposed.

On Tuesday Herring said in an interview with Cheddar that he hoped the summit would push lawmakers to approve, at least, a decriminalization bill. He said he “hoped” lawmakers and stakeholders could come away with “a concrete” plan for recreational use.

“I’m bringing experts in, I’m bringing folks from other states that have already taken these steps so that they can share the experiences that they’ve had with decriminalization and legalization,” he said, adding that Democrats control the levers of power in the state – those previous bills were quashed by Republican-led committees.

Gov. Ralph Northam (D) included cannabis law reforms in his campaign platform and has been a vocal proponent for decriminalization since his election. There is currently a legalization bill in the Legislature, sponsored by Del. Steve Heretick (D) who is one of the chairs of the caucus.

End


Federal Regulators Lift Hemp Industry Banking Barriers

Federal financial regulators will no longer treat hemp businesses as suspicious, removing a major barrier between hemp-related businesses and traditional financial services. Previously, banks were required to file Suspicious Activity Reports with the federal government whenever they opened a hemp-related business account.

The four agencies said the changes come after Congressional action legalizing hemp in 2018 and the U.S. Department of Agriculture interim rule published in October giving states and tribes the greenlight to establish hemp programs.

Rob Nichols, president of the American Bankers Association, told the New York Times that the financial reforms for hemp businesses “clarify regulatory expectations for banks.”

In 2014, the Financial Crimes Enforcement Network issued guidance outlining their cannabusiness policies, which included the SAR filings. At the time, the agency said the changes would “enhance the availability of financial services for, and the financial transparency of, marijuana-related businesses” and used policies set forth in the scrapped Obama-era Cole Memo to allow some cannabis and hemp businesses access to banking services. In 2017, FinCen said there was more than 300 banks and 100 credit unions serving the industry; however, in early 2018 then-Attorney General Jeff Sessions rescinded the cannabis industry protections outlined in the Cole Memo. Following that change, FinCen said their 2014 guidance remained in place but, by and large, cannabis companies have not had access to traditional financial services, even after the passage of the Farm Bill.

Earlier this year, U.S. Bank subsidiary Evalon stopped providing merchant services to hemp businesses and, although states have passed hemp laws, most are still waiting for USDA approval, continuing the leave the legal status of some hemp products and banking access in flux.

In September, the Democratic-led House approved the SAFE Banking Act, which would allow state-approved medical, adult-use, and hemp companies access to financial services. The bill is currently in the Republican-led Senate Committee on Banking, Housing, and Urban Affairs.

End